论文部分内容阅读
据世界制药新闻《Scrip》6月 18日 (第 2 85 9期 )报道 ,波赞 (Pozen)与葛兰素史克 (GlaxoSmithKline ,GSK)公司最近签署了一项价值为 1.6亿美元的协议 ,以联手开发长效止痛的曲普坦类 (triptan)抗偏头痛复合制剂。利好消息一经传出 ,素有经济晴雨表之称的股票市场立竿见影 ,波
June 18 (No. 859) reported by the world pharmaceutical news “Scrip” that Pozen and GlaxoSmithKline (GSK) recently signed a $ 160 million agreement to Collaborate on the development of a long-acting analgesic triptan anti-migraine complex. Once the good news came out, the stock market known as the barometer of the economy turned out to be an instant wave